Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T07:30:30.768Z Has data issue: false hasContentIssue false
  • English
  • Français

Cholinesterase Inhibitors in Vascular Cognitive Impairment

Published online by Cambridge University Press:  23 September 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue 4 , July 2013 , pp. 446 - 447
Copyright
Copyright © The Canadian Journal of Neurological 2013

References

1. Scuteri, A, Black, SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.Google Scholar
2. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357(9251):169–75.Google Scholar
3. Swartz, RH, Sahlas, DJ, Black, SE. Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis. 2003;12(1):29–36.Google Scholar
4. Bocti, C, Black, SE, Frank, C. Management of dementia with cerebrovascular component. Alzheimers Dement. 2007;3(4):398–403.CrossRefGoogle ScholarPubMed
5. Gauthier, S, Patterson, C, Chertkow, H et al. 4th Canadian consensus conference on the diagnosis and treatment of dementia. Can J Neurol Sci. 2012;39(suppl 5):S1–8.Google Scholar
6. Nasreddine, ZS, Phillips, NA, Bédirian, V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.Google Scholar
7. Hachinski, V, Iadecola, C, Petersen, RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–41.Google Scholar
8. Rockwood, K, Mitnitski, A, Black, SE, Richard, M, Defoy, I. Cognitive change in donepezil treated patients with vascular or mixed dementia. Can J Neuro Sci. 2013;40(4):564–71.Google Scholar
9. Molnar, FJ, Man-Son-Hing, M, Fergusson, D. Systematic review of measures of clinical significane employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc. 2009;57(3):536–46.CrossRefGoogle Scholar
10. Rockwood, K, Black, SE, Robillard, A, Lussier, I. Potential treatment effects of donepezil not detected in Alzheimer’s disease clinical trials: a physician survey. Int J Geriatr Psychiatry. 2004;19(10):954–60.Google Scholar
11. Black, SE, Rockwood, K, Bedard, MA, Gold, D, Lussier, I. Donepezil in Alzheimer disease: evaluating clinical meaningfulness. Alzheimer’s Dement. 2006;2(S1):S627–8.CrossRefGoogle Scholar